In this review, the authors highlight the recent progress in TD genetic research with a particular focus since 2011. They review genes involved in antipsychotic drug metabolism (pharmacokinetics) and those involved in drug targeting (pharmacodynamics), and provide a number of recommendations to move this area of research forward.
Browsing: Movement Disorders
Scientists have developed a method of detecting a molecule linked to Parkinson’s disease in samples of spinal fluid taken from patients, a step that could one day help to improve early diagnosis of the disease.
A new model is proposed that the Basal Ganglia implement the level of transition control in an extended control hierarchy, helping to explain major neurological symptoms.
Arthur Roach, Research and Development Director at Parkinson’s UK, speaks to Neurology Central to discuss recent progress and current challenges involved in Parkinson’s research. In particular, we discuss the status of the anticipated glial cell-derived neurotrophic factor study.
Striving for ‘best health’: driving up the standard of services for Parkinson’s disease patients in the UK
Neurology Central talks to David Burn, Clinical Director at Parkinson’s UK, to discuss the recently launched Parkinson’s Excellence Network, and the future of Parkinson’s disease treatment and care in the UK.
Gene-modified mesenchymal stem cells as a potential treatment for Huntington’s disease: preparing for a planned Phase I clinical trial
Available to view on demand: the UC Davis research team present an update on preclinical…
This review is a concise summary of nonmotor symptoms in both genetic and idiopathic Parkinson’s disease patients, highlighting the importance of nonmotor symptoms in research and clinical practice of Parkinson’s disease together with some of the potential differences in pathophysiology and clinical features.